Department of Pathology, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain.
Int J Oncol. 2010 Jan;36(1):107-15.
The prognostic abilities of breast cancer gene expression signatures are due mostly to the detection of proliferation activity. One of the strongest, yet simple and well-reproducible proliferation-associated prognostic factors is the mitotic activity index (MAI). However: a) counting mitotic figures is regarded by many histopathologists as cumbersome and time-consuming, and b) most available immunohistochemical markers are much weaker predictors than the MAI. We have investigated the spatio-temporal sub-cellular distribution of the Serine 2481-autophosphorylated form of mTOR (PP-mTOR(Ser2481)) during the G(1)/S-to-M-phase transition both in cultured cancer cells and in cancer tissue specimens. Using a high-resolution, automated confocal high-content imaging system, we observed that mitotic cells notably accumulated a distinct pattern of nuclear and cytoplasmic immunolabelings of PP-mTOR(Ser2481). Parallel experiments examining site-specific phosphorylation (i.e., Serine 10 and Serine 28) of the G(2)/M marker Histone H3 (PP-H3) revealed that PP-H3(Ser10/Ser28) staining efficiently detected mitotic cells from prophase until the beginning of anaphase, but not during late anaphase, telophase and cytokinesis. PP-mTOR(Ser2481) staining associated near and between separating chromosomes not only during early mitotic stages but also to the midzone and to midbody at ana/telophase through cytokinesis. We then evaluated the usefulness of PP-mTOR(Ser2481) immunostaining for improving the efficiency of mitotic counting using. Anti-PP-mTOR(Ser2481)-labeled mitotic figures (MFs) were easily seen and permitted a quick identification of mitotic hotspots in formalin-fixed cancer tissues, even at low magnification. Importantly, average mitotic counts were significantly higher when using PP-mTOR(Ser2481) staining than with the hematoxylin and eosin (H&E) protocol in breast cancer core biopsies. Mitotic count based on PP-mTOR(Ser2481) immunostaining increased tumor grade by one grade in 2 of 9 breast carcinomas. These findings warrant forthcoming studies to confirm both the accuracy and the prognostic value of PP-mTOR(Ser2481) as a novel high-contrast immunohistochemical mitosis marker in larger populations of human breast carcinomas.
乳腺癌基因表达谱的预后能力主要归因于增殖活性的检测。其中,最强但简单且可重复的与增殖相关的预后因素之一是有丝分裂活性指数(MAI)。然而:a)许多组织病理学家认为计数有丝分裂核是繁琐和耗时的,b)大多数可用的免疫组织化学标记物的预测能力远不如 MAI。我们研究了 Serine 2481 自动磷酸化形式的 mTOR(PP-mTOR(Ser2481))在培养的癌细胞和癌症组织标本中从 G1/S 期到 M 期过渡过程中的时空亚细胞分布。使用高分辨率、自动化共聚焦高内涵成像系统,我们观察到有丝分裂细胞明显积累了核和细胞质中 PP-mTOR(Ser2481)免疫标记的独特模式。平行实验检查 G2/M 标记物组蛋白 H3 的特定部位磷酸化(即丝氨酸 10 和丝氨酸 28)(PP-H3)发现,PP-H3(Ser10/Ser28)染色有效地从前期检测到有丝分裂细胞,直到后期中期开始,但不在后期中期、末期和胞质分裂期。PP-mTOR(Ser2481)染色不仅在早期有丝分裂阶段与分离的染色体附近和之间相关,而且在中期到中期和后期通过胞质分裂到中体。然后,我们使用 PP-mTOR(Ser2481)免疫染色来评估提高有丝分裂计数效率的有用性。抗 PP-mTOR(Ser2481)标记的有丝分裂核(MFs)很容易看到,并允许快速识别福尔马林固定的癌症组织中的有丝分裂热点,即使在低倍镜下也是如此。重要的是,在乳腺癌核心活检中,使用 PP-mTOR(Ser2481)染色的平均有丝分裂计数明显高于苏木精和伊红(H&E)方案。基于 PP-mTOR(Ser2481)免疫染色的有丝分裂计数在 9 例乳腺癌中有 2 例增加了一个肿瘤等级。这些发现需要进一步的研究来证实 PP-mTOR(Ser2481)作为一种新的高对比度免疫组织化学有丝分裂标记物在更大的人类乳腺癌人群中的准确性和预后价值。